Immunosuppressive therapy for ocular surface disorders

Dry Eye and Ocular Surface Disorders

Volumn , Issue , 2004, Pages 391-419

  Huang, Andrew J W ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79957468907     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (123)

1. Jabs DA, Rosenbaum JT, Foster CS, et al. Perspective: guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel Am J Ophthalmol 2000; 130:492-513.
2. Almawi WY, Melemedjian OK. Negative regulation of nuclear factor-kappaB activation and function by glucocorticoids. J Molec Endocrinol 2002; 28:69-78.
3. Pflugfelder SC. Anti-inflammatory therapy of dry eye. The Ocular Surface 2003; 1:31-36.
4. Reed JB, Morse LS, Schwab IR. High-dose intravenous pulse methylprednisolone hemisuccinate in acute Behcet retinitis. Am J Ophthalmol 1998; 125:409-411.
5. American College of Rheumatology Task Force on Osteoporosis Guidelines. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum 1996; 39:1791-1801.
6. Saag KG, Emkey R, Schnitzer TJ, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 1998; 339:292-299.
7. Conn HO, Blitzer BL. Nonassociation of adrenocorticosteroid therapy and peptic ulcer. N Engl J Med 1976; 294:473-479.
8. Piper JM, Ray WA, Daugherty JR, Griffin MR. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med 1991; 114:735-740.
9. Furst DE, Clements PJ. Immunosuppressives. In: Klippel JH, Dieppe PA, eds. Rheumatology. London: Mosby, 1998; 3.9.1-3.9.10.
10. Lacki JK, Schochat T, Sobieska M. Immunological studies in patients with rheumatoid arthritis treated with methotrexate or cyclophosphamide. Z Rheumatol 1994; 53:76-82.
11. Moore JM. Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokin 1991; 20:194-208.
12. Grochow LB, Colvin M. Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacol 1979; 4:380-394.
13. Clements PJ. Alkylating agents. In: Dixon J, Furst DE, eds. Second Line Agents in the Treatment of Rheumatic Diseases. New York: Marcel Dekker, 1991.
14. Klippel JH, Austin HA III, Balow JE, et al. Studies of immunosuppressive drugs in the treatment of lupus nephritis. Rheum Dis Clinics N Am 1987; 13:47-56.
15. Fauci AS, Wolff SM. Wegener’s granulomatosis. Studies in eighteen patients and a review of the literature. Medicine 1972; 52:535-561.
16. Wolff SM, Fauci AS, Horn RG, Dale DC. Wegener’s granulomatosis. Ann Intern Med 1974; 81:513-525.
17. Fauci AS, Haynes BF, Katz, P, Wolff SM. Wegener’s granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 1983; 98:76-85.
18. Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener’s granulomatosis: an analysis of 158 patients. Ann Intern Med 1992; 116:488-498.
19. Guillevin L, Cordier JF, Lhote F, et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener’s granulomatosis. Arthritis Rheum 1997; 40:2187-2198.
20. Buckley CE, Gills JP. Cyclophosphamide therapy of peripheral uveitis. Arch Intern Med 1969; 124:29-35.
21. Ozyazgan Y, Yardakul S, Yazici H, et al. Low dose cyclosporine A versus pulsed cyclophosphamide in Behcet’s syndrome: a single-masked trial. Br J Ophthalmol 1992; 76:241-243.
22. Rosenbaum JT. Treatment of severe refractory uveitis with intravenous cyclophosphamide. J Rheumatol 1994; 21:123-125.
23. Mondino BJ, Brown SI. Immunosuppressive therapy in ocular cicatricial pemphigoid. Am J Ophthalmol 1983; 96:453-459.
24. Foster CS. Cicatricial pemphigoid. Trans Am Ophthalmol Soc 1986; 84:527-663.
25. Masuda K, Nakajima A, Urayama A, et al. Double-masked trial of cyclosporine versus colchicine and long-term open study of cyclosporine in Behcet’s disease. Lancet 1989; 1:1093-1096.
26. Chabner BA, Allegra CJ, Curt GA, et al. Antineoplastic agents. In: Hardman JG, Limbird LE, eds. Goodman and Gilman’s the Pharmacologic Basis of Therapeutics, 9th ed. New York: McGraw-Hill, 1995; 1233-1240.
27. Muirhead N. Management of idiopathic membranous nephropathy: evidence-based recommendations. Kidney Int Suppl 1997; 70:S47-S55.
28. Mamo JG, Azzam SA. Treatment of Behcet’s disease with chlorambucil. Arch Ophthalmol 1970; 84:446-450.
29. Mamo JG. Treatment of Behcet’s disease with chlorambucil. A follow-up report. Arch Ophthalmol 1976; 94:580-583.
30. O’Duffy JD, Robertson DM, Goldstein NP. Chlorambucil in the treatment of uveitis and meningoencephalitis of Behcet’s disease. Am J Med 1984; 76:75-84.
31. Abdalla MI, Bahgat Nour E. Long-lasting remission of Behcet’s disease after chlorambucil therapy. Br J Ophthalmol 1973; 57:706-711.
32. Tessler HH, Jennings T. High-dose short-term chlorambucil for intractable sympathetic ophthalmia and Behcet’s disease. Br J Ophthalmol 1990; 74:353-357.
33. Berk PD, Goldberg JD, Silverstein MN, et al. Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. N Engl J Med 1981; 304:441-444.
34. Elion GB, Hitchings JH. Azathioprine. In: Handbook of Experimental Pharmacology. Sartolcelli AC, Johns DE, ed. Berlin: Springer-Verlag 1975; 38:404-425.
35. McKendry RJR. Purine antagonists. In: Dixon J, Furst DE, eds. Second Line Agents in the Treatment of Rheumatic Diseases. New York: Marcell Dekker, 1991.
36. Bacon PA, Salmon M. Modes of action of second line agents. Scand J Rheumatol 1987; 64(suppl):17-24.
37. El-Yazigi A, Wahab FA. Pharmacokinetics of azathioprine after repeated oral and single intravenous administration. J Clin Pharmacol 1993; 33:522-526.
38. Calin A. A placebo-controlled crossover study of azathioprine in Reiter’s syndrome. Ann Rheum Dis 1986; 95:653-655.
39. Felson DT, Anderson J. Evidence for the superiority of immunosuppressive drugs and prednisone over prednisone alone in lupus nephritis: results of a pooled analysis. N Engl J Med 1984; 311:1528-1533.
40. Tsokos GC. Immunomodulatory treatments in patients with rheumatic diseases: mechanism of action. Semin Arthritis Rheum 1987; 17:24-38.
41. Zimmerman TJ. Textbook of Ocular Pharmacology. Philadelphia: Lippincott-Raven, 1997:100-101.
42. Shah SS, Lowder CY, Schmitt MA, Wilke WS, Kosmorsky GS, Meisler DM. Low-dose methotrexate therapy for ocular inflammatory disease. Ophthalmology 1992; 99:1419-1423.
43. Kremer JM. Methotrexate and emerging therapies. Clin Exp Rheumatol 1999; 17:543-546.
44. Holz FG, Krastel H, Breitbart A, et al. Low-dose methotrexate treatment in noninfectious uveitis resistant to corticosteroids. Ger J Ophthalmol 1992; 1:142-144.
45. Dev S, McCallum RM, Jaffe GJ. Methotrexate treatment for sarcoid-associated panuveitis. Ophthalmology 1999; 106:111-118.
46. Tugal-Tutkan I, Havrlikova K, Power WJ, Foster CS. Changing patterns in uveitis of childhood. Ophthalmology 1996; 103:375-383.
47. Giannini EH, Brewer EJ, Kuzmina N, et al. Methotrexate inresistant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebocontrolled trial. N Engl J Med 1992; 326:1043-1049.
48. Wallace CA. The use of methotrexate in childhood rheumatic disease. Arthritis Rheum 1998; 41:381-391.
49. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporine and corticosteroids for prevention of acute rejection. Lancet 1995; 345:1321-1325.
50. The Tricontinental Mycophenolate Mofetil Renal Transplantation Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996; 61:1029-1037.
51. Larkin G, Lightman S. Mycophenolate mofetil. A useful immunosuppressive in inflammatory eye disease. Ophthalmology 1999; 106:370-374.
52. Kilmartin DJ, Forrester JV, Dick AD. Rescue therapy with mycophenolate mofetil in refractory uveitis. Lancet 1998; 352:35-36.
53. Reis A, Reinhard T, Voiculescu A, et al. Mycophenolate mofetil versus cyclosporin A in high-risk keratoplasty. Br J Ophthalmol 1999; 83:1268-1271.
54. Fox RI. Mechanism of action of leflunomide in rheumatoid arthritis. J Rheum 1998; 53(suppl):20-26.
55. New drugs for rheumatoid arthritis. Med Lett Drugs Ther 1998; 40:110-112.
56. Strand V, Cohen S, Schiff M, et al. Treatment of active rheumatoid arthritis with leftunomide compared to placebo and methotrexate. Arch Intern Med 1999; 159:2542-2550.
57. Smollen JS. Efficacy and safety of leflunomide compared with placebo and sulfasalazine in active rheumatoid arthritis. Lancet 1999; 353:259-266.
58. Weinblatt ME, Kremer JM, Coblyn JS, et al. Pharmacokinetics, safety and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum 1999; 42:1322-1329.
59. Gerber DA, Bonham CA, Thomson AW. Immunosuppressive agents: recent developments in molecular action and clinical application. Transplant Proc 1998; 30:1573-1579.
60. Matsuda S, Koyasu S. Mechanisms of action of cyclosporin. Immunopharmacology 2000 47:119-125.
61. Keown PA, Primmet DR. Cyclosporine: the principal immunosuppressant for renal transplantation. Transplant Proc 1998; 30:1712-1715.
62. Nussenblatt RB, Palestine AG, Chan CC. Cyclosporine A therapy in the treatment of intraocular inflammatory disease resistant to systemic corticosteroids and cytotoxic agents. Am J Ophthalmol 1983; 96:275-282.
63. Nussenblatt RB, Palestine AG, Chan CC, et al. Randomized double-masked study of cyclosporine compared to prednisone in the treatment of endogenous uveitis. Am J Ophthalmol 1991; 112:138-146.
64. Walton RC, Nussenblatt RB, Whitcup SM. Cyclosporine therapy for severe sightthreatening uveitis in children and adolescents. Ophthalmology 1998; 105:2028-2034.
65. Masuda K, Nakajima A, Urayama A, Nakae K, Kogure M, Inaba G. Doublemasked trial of cyclosporine versus colchicine and long-term open study of cyclosporine in Behcet’s disease. Lancet 1989; 1:1093-1096.
66. Hong JC, Kahan BD. Immunosuppressive agents in organ transplantation: past, present, and future. Semin Nephrol 2000; 20:108-125.
67. Keown PA. New immunosuppressive strategies. Curr Opin Nephrol Hypertens 1998; 7:659-663.
68. Shimazaki J, Kaido M, Shinozaki N, et al. Evidence of long-term survival of donorderived cells after limbal allograft transplantation. Invest Ophthalmol Vis Sci 1999; 40:1664-1668.
69. Tsubota K, Satake Y, Kaido M, et al. Treatment of severe ocular-surface disorders with corneal epithelial stem-cell transplantation. N Engl J Med 1993; 340:1697-1703.
70. Holland EJ, Olsen TW, Ketcham JM, et al. Topical cyclosporin A in the treatment of anterior segment inflammatory disease. Cornea 1993; 12:413-419.
71. Milani JK, Pleyer U, Dukes A, et al. Prolongation of corneal allograft survival with liposome-encapsulated cyclosporine in the rat eye. Ophthalmology 1993; 100:890-896.
72. Sall K, Stevenson OD, Mundorf TK, Reis BL. Two multicenter, randomized studies of the efficacy and safety of cyclosporin ophthalmic emulsion in moderate to severe dry eye disease. Ophthalmology 2000; 107:631-639.
73. Kaswan RL, Salisbury MA, Ward DA. Spontaneous canine keratocon-junctivitis sicca. A useful model for human keratoconjunctivitis sicca: treatment with cyclosporin eye drops. Arch Ophthalmol 1989; 107:210-1216.
74. Gunduz K, Ozdemir O. Topical cyclosporin treatment of keratoconjunctivitis sicca in secondary Sjogren’s syndrome. Acta Ophthalmol 1994; 72:438-442.
75. Laibovitz RA, Solch S, Andriano K, O’Connell M, Silverman MH. Pilot trial of cyclosporine 1% ophthalmic ointment in the treatment of keratoconjunctivitis sicca. Cornea 1993; 12:315-323.
76. Stevenson D, Tauber J, Reis BL. Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging randomized trial. The Cyclosporin A Phase 2 Study Group. Ophthalmology 2000; 107:967-974.
77. Brignole F, Pisella PJ, De Saint Jean M, et al. Flow cytometric analysis of inflammatory markers in KCS: 6-month treatment with topical cyclosporin A. Invest Ophthalmol Vis Sci 2001; 42:90-95.
78. Turner K, Pflugfelder SC, Ji Z, et al. Interleukin-6 levels in the conjunctival epithelium of patients with dry eye disease treated with cyclosporine ophthalmic emulsion. Cornea 2000; 19:492-496.
79. Kunert KS, Tisdale AS, Stern ME, et al. Analysis of topical cyclosporine treatment of patients with dry eye syndrome: effect on conjunctival lymphocytes. Arch Ophthalmol 2000; 118:1489-1496.
80. Kervick GN, Pflugfelder SC, Haimovici R, et al. Paracentral rheumatoid corneal ulceration. Clinical features and cyclosporine therapy. Ophthalmology 1992; 99:80-88.
81. Xu KP, Wu Y, Zhou J, Zhang X. Survival of limbal stem cell allografts after administration of Cyclosporin A. Cornea 1999; 18:159-165.
82. Suzuki N, Kaneko S, Ichino M, Mihara S, Wakisaka S, Sakane T. In vivo mechanisms for the inhibition of T lymphocyte activation by long-term therapy with tacrolimus (FK-506): experience in patients with Behcet’s disease. Arthritis Rheum 1997; 40:1157-1167.
83. Mochizuki M, Masuda K, Sakane T, et al. A clinical trial of FK506 in refractory uveitis. Am J Ophthalmol 1993; 115:763-769.
84. Ishioka M, Ohno S, Nakamura S, et al. FK506 treatment of noninfectious uveitis. Am J Ophthalmol 1994; 118:723-729.
85. Kilmartin DJ, Forrester JV, Dick AD. Tacrolimus (FK506) in failed cyclosporine A therapy in endogenous posterior uveitis. Ocul Immunol Inflamm 1998; 6:101-109.
86. Sloper CM, Powell RJ, Dua HS. Tacrolimus (FK506) in the treatment of posterior uveitis refractory to cyclosporine. Ophthalmology 1999; 106:723-728.
87. Vanrenterghem YF. Which calcineurin inhibitor is preferred in renal transplantation: tacrolimus or cyclosporine?. Curt Opin Nephrol Hypertens 1999; 8:669-674.
88. Fung JJ, Abu-Elmagd K, Jain AB, et al. A randomized trial of primary liver transplantation under immunosuppression with FK506 versus cyclosporine. Transplant Proc 1991; 23:2977-2983.
89. Fung JJ, Eliasziw M, Todo S, et al. The Pittsburgh randomized trial of tacrolimus compared to cyclosporine for hepatic transplantation. J Am Coll Surg 1996; 183:117-125.
90. Dua HS, Azuara-Blanco A. Allo-limbal transplantation in patients with limbal stem cell deficiency. Br J Ophthalmol 1999; 83:414-419.
91. Kobayashi C, Kanai A, Nakajima A, Okumura K. Suppression of corneal graft rejection in rabbits by a new immunosuppressive agent, FK-506. Transplant Proc 1989; 21:3156-3158.
92. Cacciarelli TV, Green M, Jaffe R, et al. Management of posttransplant lymphoproliferative disease in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy. Transplantation 1998; 66:1047-1052.
93. MacDonald A, Scarola J, Burke IT, Zimmerman JJ. Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus. Clin Ther 2000; 22(suppl B):101-121.
94. Kaplan B, Meier-Kriesche Hid, Napoli KL, Kahan BD. The effects of relative timing of sirolimus and cyclosporine microemulsion formulation coadministration on the pharmacokinetics of each agent. Clin Pharmacol Ther 1998; 63:48-53.
95. Dinarello CA. Proinflammatory cytokines. Chest 2000; 118:503-508.
96. Li DQ, Lokeshwar BL, Solomon A, et al. Regulation of MMP-9 in human corneal epithelial cells. Exp Eye Res 2001; 73:449-459.
97. Sack RA, Beaton A, Sathe S, et al. Towards a closed eye model of the pre-ocular tear layer. Prog Retin Eye Res 2000; 19:649-668.
98. Smith VA, Rishmawi H, Hussein H, Easty DL. Tear film MMP accumulation and corneal disease. Br J Ophthalmol 2001; 85:147-153.
99. Afonso AA, Sobrin L, Monroy DC, et al. Tear fluid gelatinase B activity correlates with IL-1a concentration and fluorescein clearance in ocular rosacea. Invest Ophthalmol Vis Sci 1999; 40:2506-2512.
100. Sobrin L, Liu Z, Monroy DC, et al. Regulation of stromelysin (MMP-3) activity in human tear fluid and corneal epithelial culture supernatant. Invest Ophthalmol Vis Sci 2000; 41:1703-1709.
101. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001; 17:463-516.
102. Moreland L, Schiff MH, Baumgartner SW, et al. Recombinant human TNF receptor (p75):FC fusion protein in rheumatoid arthritis: a multicenter, randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999; 130:478-486.
103. Weinblatt M, Kremer JM, Bankhurst AD, et al. A trial of etanecept, a recombinant tumor necrosis factor:Fc fusion protein in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340:253-259.
104. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple infusions of anti-tumor necrosis factor monoclonal antibody combined with low-dose methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41:1556-1563.
105. Bresnihan B, Alvaro-Garcia JM, Cobby M, et al. Treatment of rheumatoid arthritis with recombinant interleukin-1 receptor antagonist. Arthritis Rheum 1998; 41:2196-2204.
106. Caldwell J, Gendreau RM, Furst D. A pilot study using a staph protein A column (Prosorba) to treat refractory rheumatoid arthritis. J Rheum 1999; 26:1657-1662.
107. Felson DT, LaValley MP, Baldassare AR, et al. The Prosorba column for treatment of refractory rheumatoid arthritis. Arthritis Rheum 1999; 42:2153-2159.
108. Wiseman LR, Faulds D. Daclizumab: a review of its use in the prevention of acute rejection in renal transplant recipients. Drugs 1999; 58:1029-1042.
109. Nussenblatt RBF, Fortin E, Schiffman R, et al. Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a Phase I/II clinical trial. Proc Natl Acad Sci USA 1999; 96:7462-7466.
110. Edwards JC. Sustained improvement in rheumatoid arthritis following blymphocyte depletion. Arthritis Rheum 2000; 43(suppl 9):S391.
111. Hoffman F, Kruse HA, Meinhold H, et al. Interleukin-2 receptor targeted therapy with monoclonal antibodies in the rate corneal graft. Cornea 1994; 13:440-446.
112. Ippoliti G, Fronterre A. Usefulness of CD3 or CD6 monoclonal antibodies in the treatment of acute corneal graft rejection. Transplant Proc 1989; 21:3133.
113. Imbach P, Wagner HP, Berthtold W, et al. Intravenous immunoglobulin versus oral corticosteroids in acute immune thrombocytopenic purpura in childhood. Lancet 1985; 2:464-468.
114. Cosi V, Lombardi M, Piccolo G, Erbetla A. Treatment of myasthenia gravis with high-dose intravenous immunoglobulin. Acta Neurol Scand 1991; 84:81-84.
115. Francioni C, Galeazzi M, Fioravanti A, et al. Long-term i.v. Ig treatment in systemic lupus erythematosus. Clin Exp Rheumatol 1994; 12:163-168.
116. Achiron A, Barek Y, Goren M, et al. Intravenous immune globulin in multiple sclerosis: clinical and neuroradiological results and implications for possible mechanisms of action. Clin Exp Immunol 1996; 104(suppl 1):67-70.
117. Tumiati B, Casoli P, Veneziani M, Rinaldi G. High-dose immunoglobulin therapy as an immunomodulatory treatment of rheumatoid arthritis. Arthritis Rheum 1992; 35:1126-1133.
118. Jordan SC, Toyoda M. Treatment of autoimmune diseases and systemic vasculitis with pooled human intravenous immune globulin. Clin Exp Immunol 1994; 97(suppl 1):31-38.
119. Rosenbaum JT, George R, Gordon C. The treatment of refractory uveitis with intravenous immunoglobulin. Am J Ophthalmol 1999; 127:545-549.
120. Strand V. Proposed mechanisms for the efficacy of intravenous immunoglobulin treatment. In: Lee ML, Strand V, eds. Intravenous Immunoglobulins in Clinical Practice. New York: Marcel Dekker, 1997; 23-36.
121. Klaesson S, Ringden O, Markling L, et al. Immune modulatory effects of immunoglobulins on cell-mediated immune responses in vitro. Scand J Immunol 1993; 38:477-484.
122. Foster CS, Ahmed AR. Intravenous immunoglobulin therapy for ocular cicatricial pemphigoid. A preliminary study. Ophthalmology 1999; 106:2136-2143.
123. Nussenblatt RB, Gery I, Weiner HL, et al. Treatment of uveitis by oral administration of retinal antigens: results of a Phase I/II randomized masked trial. Am J Ophthalmol 1997; 123:583-592.